Overall survival（OS）with palbociclib（PAL）+ fulvestrant（FUL）in women with hormone receptor–positive（HR+）， human epidermal growth factor receptor 2–negative（HER2-）advanced breast cancer（ABC）: Updated analyses from PALOMA-3.

PALOMA-3研究更新：palbociclib（PAL）+ fulvestrant（FUL）治疗HR+/HER2-晚期乳腺癌（ABC）的总生存（OS）结果。

作者：Massimo Cristofanilli， Hope S. Rugo， Seock-Ah Im，et al.

摘要号：1000

Updated overall survival（OS）results from the phase III MONALEESA-3 trial of postmenopausal patients（pts）with HR+/HER2- advanced breast cancer（ABC）treated with fulvestrant（FUL）± ribociclib（RIB）.

MONALEESA-3研究更新：绝经后HR+/HER2-晚期乳腺癌患者（ABC）接受fulvestrant（FUL）±ribociclib（RIB）治疗的OS结果。

作者：Dennis J. Slamon， Patrick Neven， Stephen K.Chia， et al.

摘要号：1001

Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy（DAWNA-1）: A multicenter， randomized， phase 3 study.

Dalpiciclib对比安慰剂加氟维司群治疗既往内分泌治疗复发或进展的HR+/HER2-晚期乳腺癌（DAWNA-1）：一项多中心、随机、3期研究

作者：徐兵河等。

摘要号：1002

Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

sysucc-002研究：曲妥珠单抗联合内分泌或化疗一线治疗激素受体阳性和HER2阳性的转移性乳腺癌

作者：袁中玉等。

摘要号：1003

Results from VERONICA: A randomized， phase II study of second-/third-line venetoclax（VEN）+ fulvestrant（F）versus F alone in estrogen receptor（ER）-positive， HER2-negative， locally advanced， or metastatic breast cancer（LA/MBC）.

VERONICA：二线/三线应用venetoclax（VEN）+ fulvestrant（F）对比单药F治疗ER+/HER2-局部晚期或转移性乳腺癌（LA/MBC）的随机II期研究结果。

作者：Geoffrey J. Lindeman， Rebecca Bowen， Katarzyna J. Jerzak， et al.

摘要号：1004

Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer（MBC）.

与治疗有关的副作用和有关剂量评估以维持生活质量的观点：一项由倡导者主导的转移性乳腺癌（MBC）患者调查的结果。

作者：Anne L. Loeser， Jeffrey M. Peppercorn， Mark E. Burkard， et al.

摘要号：1005

The tumor microenvironment（TME）and atezolizumab + nab-paclitaxel（A+nP）activity in metastatic triple-negative breast cancer（mTNBC）: IMpassion130.

IMpassion130研究：转移性三阴性乳腺癌（mTNBC）中肿瘤微环境（TME）和atezolizumab + nab-紫杉醇（A + nP）活性

作者：Leisha A. Emens， Leonard D. Goldstein， Peter Schmid，  et al.

摘要号：1006

Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer（FUTURE-C-PLUS）: A prospective， single-arm， phase 2 study.

FUTURE-C-plus研究：一项前瞻性、单臂、2期研究——法米替尼联合卡瑞利珠单抗+白蛋白紫杉醇一线治疗免疫调节型晚期三阴性乳腺癌。

作者：陈力等

摘要号：1007

Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer（MBC）.

每周3次卡巴他赛与每周紫杉醇化疗一线治疗HER2阴性转移性乳腺癌（MBC）的随机多中心试验。

作者：Amit Bahl， Jeremy Braybrooke， Alicia Bravo， et al.

摘要号：1008

Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.

MINDACT研究中70基因超低风险患者的结局。

作者：Josephine Lopes Cardozo， Caroline Drukker， Marjanka Schmidt，et al.

摘要号：500

Breast Cancer Index（BCI）and prediction of benefit from extended aromatase inhibitor（AI）therapy（tx）in HR+ breast cancer: NRG oncology/NSABP B-42.

HR+乳腺癌的乳腺癌指数（BCI）和延长芳香化酶抑制剂（AI）治疗（tx）获益的预测：NRG oncology/NSABP B-42。

作者：Eleftherios P. Mamounas， Hanna Bandos， Priya Rastogi，et al.

摘要号：501

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy（ELT）in the NRG Oncology/NSABP B-42 trial.

NRG Oncology / NSABP B-42试验中，70基因的MammaPrint检测法可用于预测延长来曲唑疗法（ELT）的获益。

作者：Priya Rastogi， Hanna Bandos， Peter C. Lucas，et al.

摘要号：502

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

HR-/HER2 +早期乳腺癌中降级新辅助治疗帕妥珠单抗+曲妥珠单抗加或不加周疗紫杉醇：ADAPT-HR- / HER2 +生物标志物和生存结果。 

作者：Nadia Harbeck， Oleg Gluz， Matthias Christgen，et al.

摘要号：503

Prognostic impact of recurrence score， endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.

WSG-ADAPT HR+/HER2-化疗试验的结果：高危luminal乳腺癌复发评分、内分泌反应和临床病理因素对预后的影响

作者：Oleg Gluz， Ulrike Nitz， Matthias Christgen，et al.

摘要号：504

Neoadjuvant talazoparib in patients with germline BRCA1/2（gBRCA1/2）mutation-positive， early HER2-negative breast cancer（BC）: Results of a phase 2 study.

新辅助talazoparib用于胚系BRCA1/2（gBRCA1/2）突变阳性、早期HER2-乳腺癌（BC）患者的一项2期研究的结果。

作者：Jennifer K. Litton， Joseph T. Beck， Jason M. Jones， et al.

摘要：505

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer（TNBC）.

Durvalumab可改善TNBC的长期预后：GeparNUEVO II期随机研究结果表明，除了基于蒽环类/紫杉烷类的新辅助化疗以外，新辅助durvalumab也可用于早期三阴性乳腺癌（TNBC）。

作者：Sibylle Loibl， Andreas Schneeweiss， Jens B. Huober， et al.

摘要号：506

Evaluation of intra-tumoral（IT）SD-101 and pembrolizumab（Pb）in combination with paclitaxel（P）followed by AC in high-risk HER2-negative（HER2-）stage II/III breast cancer: Results from the I-SPY 2 trial.

评估肿瘤内（IT）SD-101和pembrolizumab（Pb）联合紫杉醇（P）序贯AC治疗高危HER2阴性（HER2-）II / III期乳腺癌的效果：来自I-SPY2研究的结果。

作者：Amy J. Chien， Hatem H. Soliman， Cheryl A. Ewing， et al.

摘要号：508

A randomized phase III post-operative trial of platinum-based chemotherapy（P）versus capecitabine（C）in patients（pts）with residual triple-negative breast cancer（TNBC）following neoadjuvant chemotherapy（NAC）: ECOG-ACRIN EA1131

ECOG-ACRIN EA1131研究：新辅助化疗（NAC）后仍有残留的三阴性乳腺癌（TNBC）患者术后铂类化疗（P）对比卡培他滨（C）治疗的III期随机临床试验。

作者：Ingrid A. Mayer， Fengmin Zhao， Carlos L. Arteaga， et al.

摘要号：605